Publications Update # 1
- A must read paper comparing the genomic and immune landscape between the long-term survivors (~10 years) to those with short survival (~2 years). Short survival patient had much higher CCNE 1 mutation rates compared to those with long-term survival (much higher HRD mutations).
2. Another paper discussing the role of High-level Amplification of CCNE1 (~9% of all HGSOC patients) and its association with worse survival.
3. This phase II trial investigated Adavosertib in tumors with CCNE1 amplification. From the abstract:
Fourteen patients with epithelial ovarian cancer showed an ORR of 36% (95% CI, 13 to 65) and SD ≥ 6 months/PR of 57% (95% CI, 29 to 82), a median progression-free survival duration of 6.3 months (95% CI, 2.4 to 10.2), and a median overall survival duration of 14.9 months (95% CI, 8.9 to 20.9).